Johnson & Johnson, the maker of health products from Band-Aids to biologic drugs, spent nearly $1.6 million in the second quarter lobbying on health care reform and multiple bills that could boost its revenue, according to a recent disclosure form.
Johnson and Johnson, which spent $1.7 million on lobbying in the year-ago period, this year lobbied on patent reform provisions, federal budget legislation and various aspects of health reform. Those included bills to require research comparing the effectiveness of medications and other medical treatments, mandate that health products come with effectiveness information and provide quality health care to all Americans.The world's biggest maker of health care products with about $64 billion in annual revenue, the company lobbied to extend the Children's Health Insurance Program to more children and to expand certain public health programs, such as the National Health Service Corps.
J&J, which makes the HIV medicine Prezista, lobbied on two bills involving Medicaid coverage for poor people infected with the virus that causes AIDS.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
